Author: Shernide Delva
The controversy surrounding the Megyn Kelly Sunday Night show continues. The first investigation piece on drug addiction focused on issues plaguing the South Florida recovery community.
Now, Megyn Kelly returns to cover addiction treatment, and this time her show is highlighting another polarizing subject: harm reduction programs. On Sunday night, Megyn Kelly’s shows featured The Sinclair Method. The Sinclair Method is a harm reduction treatment program that allows patients who struggle with alcohol use disorder to continue drinking.
The segment introduces viewers to Marisa, a 25-year-old binge drinker. The crew follows Marisa around for day one of her introduction to The Sinclair Method.
First Marisa sees a doctor, who gives her a prescription. Shortly after taking the prescription, she has a drink. According to Marisa, her intense cravings to binge disappears.
“I feel like I could have another drink or not have another drink and be totally fine,” she tells the camera.
The apparent miracle pill is naltrexone, a commonly used opioid antagonist typically used to treat heroin addiction. However, under The Sinclair Method, the drug is used to treat alcoholism.
“The drug blocks pleasure receptors in the brain―a buzzkill,” Melvin explains in a voiceover. “And when combined with psychotherapy sessions, the theory goes, eventually the cravings go away.”
Essentially, the idea behind the program is patients take naltrexone before drinking and over time, the desire to excessively drink diminishes. For Marisa, the unorthodox treatment seems to have worked. Only three months after starting the treatment, she told NBC she had lost her drive to drink.
Still, this approach is far from traditional. The 12-step model of addiction promotes abstinence only treatment. The show highlighted an interview with Hazelden Betty Ford’s executive director, Chris Yadron.
“The 12 steps are crucial because it’s a spiritual program of recovery,” he told Melvin.
Dr. Mark Willenbring who once ran the NIH’s alcohol recovery research defended The Sinclair Method, added that 12-step approaches do not rely on modern science.
“We don’t send someone with diabetes to a spa for a month, teach them diet and exercise and then say, ‘Go to support groups, but don’t take insulin.’ I mean, that’s the absurdity of what we’re doing now,” he said. “We’re still providing the same pseudo treatment that we provided in 1950. And 85% of rehabs in the country are 12-step rehabs. People don’t have any choice.”
The tension between abstinence-based and harm-reduction approaches to treatment has created a long-standing controversy in the recovery community. Throughout the segment, tweets were displayed from people who were for and against harm reduction strategies.
“This is very troublesome to see that some doctors are giving people with a thinking disease a “magic” pill,” tweeted one user.
Others felt the treatment option provides another solution than the standard abstinence-only approach. We’ve seen harm reduction programs like Moderation Management receive massive criticism, specifically after the founder, Audrey Kishline, killed a 12-year old girl and her father while driving in an alcoholic blackout.
Overall, programs like these remain controversial and risky. It is best to get treatment to address the underlying issues behind your addiction. If you are struggling with mental illness or addiction, please call now.
CALL NOW 1-800-951-6135
Author: Shernide Delva
Each year, more than 300 million people are affected by depression. Depression is a debilitating illness that is difficult to treat.
What if there was one gene that played a key role in depression? Furthermore, what if that gene could be identified and even manipulated to actually treat depression?
Shockingly, this could all be a possibility. Researchers have discovered a gene that may play a central role in depression. This gene either protects us from stress or triggers a downward spiral depending on its level of activity.
The study was conducted by researchers at the University of Maryland School of Medicine (UM SOM). It was the first to pinpoint in detail how one particular gene, known as Slc6a15, is a key role in depression. The study found the same link in both animals and humans.
“This study really shines a light on how levels of this gene in these neurons affects mood,” said the senior author of the study, Mary Kay Lobo, an assistant professor in the Department of Anatomy and Neurobiology.
“It suggests that people with altered levels of this gene in certain brain regions may have a much higher risk for depression and other emotional disorders related to stress.”
Potential Treatment Solution?
A study like this could help with treating depression in the future, and that help is desperately needed.
Nearly 800,000 people die annually from suicide. It is the second leading cause of death among people between the ages of 15 to 29. Beyond that, depression destroys the quality of life for tens of millions of patients, and their families suffer too. Although environmental factors play a significant role in many cases of depression, genetics are equally as important.
This is not the first time this gene was studied. Back in 2006, Dr. Lobo and her colleagues found that the Slc6a15 gene was common in specific neurons in the brain. They recently demonstrated that these neurons were important in depression.
Connection to Anhedonia
Her lab decided to investigate the specific role these neurons have in depression. In the latest study, she and her team focused on a particular area of the brain called the nucleus accumbens. This region is crucial in the brain’s “reward circuit.”
When you eat a delicious meal or participate in any kind of enjoyable experience, neurons in the nucleus accumbens are activated letting you know the experience is enjoyable. When a person is depressed, it ‘s hard to experience any kind of enjoyment, a condition known as anhedonia.
Researchers discovered subset neurons in the nucleus accumbens called D2 neurons. These neurons respond to the neurotransmitter dopamine, which plays a central role in the reward circuit.
Mainly, these subset neurons responded to feel good chemicals like dopamine which is lacking in those with depression. Next, they studied mice susceptible to depression. These mice tended to withdraw from activities and exhibit behavior indicating depression such as social withdrawal and lack of interest in the food they would normally enjoy.
Dr. Lobo found that when the mice were subject to social stress, the levels of the Slc6a15 gene in the D2 neurons of the nucleus accumbens was noticeably reduced. The researchers also studied mice in which the gene had been reduced in D2 neurons. When those mice were subjected to stress, they also exhibited signs of depression. Furthermore, when researchers increased the levels of Slc6a15 levels in D2 neurons, the mice showed a resilient response to stress.
So what does this mean?
Next, Dr. Lobo looked at brains of humans who had a history of major depression and who had committed suicide. In the same region of the brain as the mice, the gene Slc6a15 was reduced. This indicates that the link between gene and behavior is found in both humans and mice.
In the future, manipulating these genes could help improve depression. While it is still unclear how Slc6a15 operates in the brain, Dr. Lobo states it may work by altering neurotransmitter levels in the brain.
This research could lead to therapies that focus specifically on this particular gene to treat depression. If you are struggling with substance abuse or mental illness, call now. Do not wait.
CALL NOW 1-800-951-6135
Author: Shernide Delva
In the past, we’ve talked about the effects opioids have had on the workforce. We’ve analyzed issues such as how employers handle addiction and how to take time off to seek treatment.
However, a recent article delved further into the complications opioid use have on the workforce.
What if I told you that fewer people were looking for a job or had a job because of opioid addiction?
It turns out, this is a real possibility.
Workforce participation is defined as the number of people working or actively looking for work. Workforce participation has decreased significantly, despite increases in job creation and decreases in unemployment.
One economist points out this decrease may be due to an unlikely cause: opioid addiction.
“Use of both legal prescription pain relievers and illegal drugs is part of the story of declining prime-age participation, especially for men, and this reinforces our doubts about a rebound in the participation rate,” said David Mericle, senior U.S. economist at Goldman Sachs, who prepared a report on the issue earlier this week.
This belief is contrary to recent CBS reports which noted that the decline in workplace participation was due to less demand for lower skilled workers and rising disability rates.
On the contrary, David Mericle argues the reduction in workplace participation has more to do with opioid abuse.
“Data on substance abuse treatment episodes also reinforce the narrative: Of admissions of individuals not in the labor force, 58% described themselves as being out of the labor force for ‘other’ reasons—meaning they aren’t students, disabled, retired, inmates or homemakers—and 47% of these admissions were for opioids, well above the average rate,” he wrote in the report.
This issue simply cannot be ignored.
The opioid crisis has a clear impact on workplace participation because those who struggle with opioid addiction may quit their jobs or get fired. Then, those same people will not apply for other jobs due to their concerns regarding their ability to meet the demands of the work or even pass a drug screening.
“Especially in companies that hire drivers, we hear a lot about how the drug tests are a problem there,” Gad Levanon, chief economist for North America of The Conference Board told CBS. “Many of [the applicants] don’t pass it, so they can’t hire them—and they don’t know many aren’t even trying.”
Opioid abuse is rampant in the same demographic that has seen the largest decline in workforce participation. Opioid use is prevalent in rural areas which commonly struggle economically. A report stated that 22 out of 25 most impacted by opioid abuse are in rural areas or the South.
Which Came First: Economic Hardships or Opioid Abuse?
Mericle did not elaborate on how economic hardships may have influenced opioid abuse in these rural areas or vice versa. He concluded that the opioid epidemic “is intertwined with the story of declining prime-age participation, especially for men.” Essentially, it is hard to determine what led to what.
What do you think? Should we blame the decrease in workforce participation on opioid abuse or do other factors play a more significant role? Regardless of the effect opioids have on the workforce, the reality remains that it is a serious problem.
People who struggle with addiction often quit their jobs, or refuse to look at all because of their addiction. Therefore, a push for treatment is critical. If you are struggling with substance abuse or mental illness, call now. Do not wait.
CALL NOW 1-800-951-6135
Author: Shernide Delva
The United States has slowly begun to see more and more states approve medical and even recreational marijuana. But the U.S. is far from the only country seeing major shifts in marijuana policies.
Greece just joined six other European Union countries in approving some form of medical cannabis. Greece is “turning its page” on drug policy by allowing qualified citizens to access medical cannabis. The announcement by Greek officials occurred on June 30 at a press conference.
“Greece is now included in countries where the delivery of medical cannabis to patients in need is legal,” according to Greece’s Government Gazette.
Now that the government had reclassified cannabis from Table A to Table B, it is now possible for certain patients to access marijuana for medical purposes legally. This move is like moving cannabis from Schedule I to Schedule II of the United States’ Controlled Substances Act.
In the U.S., cannabis is still classified under Schedule I, alongside heroin and LSD. Although various states permit marijuana use, it is still not legal on a federal level. Drugs like oxycodone, methadone, and methamphetamine are in Schedule II, a less restrictive drug category.
With these new implementations, Greece can now import products from other countries like Canada and the United States. There are qualifying conditions required by the Ministry of Health that patients must have to access medical marijuana.
These health conditions include:
- Chronic or Neuropathic Pain
- Nausea & vomiting from chemotherapy
- Some eating disorders
“From now on, the country is turning its page, as Greece is now included in countries where the delivery of medical cannabis to patients in need is legal,” said Greek Prime Minister Alexis Tsipras.
Greece joins six other European Union countries that have approved medical cannabis in some form.
Other countries include:
- The Czech Republic
- The Netherlands
Germany is a recent addition to the list. Their law went into effect this past March to help “critically ill” citizens.
Another country approving cannabis in June is Mexico, where the new law passed legislation with overwhelming support.
A country like Greece supporting medical marijuana is a major shift in the country’s mentality. Greece has a long known history of strict anti-drug laws. However, the debt-ridden country is moving in a different direction. The government legalized the processing of hemp in April, “ending 60 years of prohibition of the traditional, non-psychoactive plant,” Leafly reported at the time.
Hemp is a variety of the Cannabis sativa plant species that is grown specifically for mass use. Although hemp and marijuana come from the same plant, they are distinctively different. Hemp has low THC levels, which means it does not produce a high. Hemp is processed into a variety of useful products including paper, textiles, clothing, plastics, biofuel, and food.
Marijuana reform remains a controversial topic. However as the medical benefits of cannabis continue to reveal themselves, more countries are opening up to the idea of legalization. What do you think about the recent legalization of medical marijuana in Greece?
Like any substance, marijuana can be abused. If you are struggling with substance abuse or addiction, please seek help. Regardless of whether a drug is legalized or not, if you feel out of control with your substance use, please reach out. We want to help.
CALL NOW 1-800-951-6135
Author: Shernide Delva
Chronic pain can be extremely difficult to manage. Pain management involves a variety of treatment options, but one area that desperately needs attention is the psychological impact of chronic pain. According to researchers, about half of adults with chronic pain also experience anxiety or mood disorders like depression.
The findings, published online in the Journal of Affective Disorders, highlight the need to offer treatment and resources to those struggling with the psychological impact of chronic pain.
“The dual burden of chronic physical conditions and mood and anxiety disorders is a significant and growing problem,” said Silvia Martins, MD, Ph.D., associate professor of Epidemiology at the Mailman School of Public Health, and senior author.
The research examined data to analyze the associations between mood and anxiety disorder and self-reported chronic physical conditions. 5,037 participants in São Paulo, Brazil participated in the interview process.
Among individuals with mood disorders, chronic pain was reported by 50 percent, followed by respiratory disease at 33 percent, cardiovascular disease at 10 percent, arthritis by 9 percent, and diabetes by 7 percent.
Anxiety disorders were also common among those with chronic pain reported at 45 percent, and respiratory at 30 percent, as well as arthritis and cardiovascular disease, each 11 percent.
“These results shed new light on the public health impact of the dual burden of physical and mental illness,” said Dr. Martins. “Chronic disease coupled with a psychiatric disorder is a pressing issue that health providers should consider when designing preventive interventions and treatment services — especially the heavy mental health burden experienced by those with two or more chronic diseases.”
Chronic Pain and Painkiller Addiction
One common treatment for chronic pain is the use of prescription painkillers. Opioids like Vicodin, OxyContin, and Percocet affect specific parts of the brain that reduce the perception of pain. However, along with reducing the perception of pain, these medications also release feel-good chemicals in the brain, often leading to dependence.
With this study, it is clear why chronic pain sufferers are susceptible to opioid dependence due to a variety of factors including the need for feel-good chemicals like dopamine. Chemicals like dopamine and serotonin are lacking in those with depression and anxiety.
Many patients who take prescription painkillers do so without forming any dependence. In some, opioid use generates negative side effects such as nausea, making them more unwilling to use the drug’s long-term. Still, some individuals are so desperate for pain relief, that they take larger doses than prescribed more frequently. Not long after, a full-blown addiction develops.
It is important to note that there is no way to know whether a prescription painkiller user will develop an addiction to opioids. However, factors like having a family history of addiction, struggling with mood disorders such as depression or anxiety, or experiencing a past trauma, such as physical or sexual abuse all increase the risk. Those who have struggled with previous addiction are at a higher risk as well.
Another dangerous aspect of opioid addiction is that it often leads to heroin use. Health officials confirm that this is not uncommon. Because painkillers are more difficult to obtain and more expensive, many users turn to using heroin. Heroin is in a similar drug classification as opioids and is easy to obtain for cheap on the street.
Overall, this study says a lot about the way mental disorders and addiction often go hand in hand. That’s why so many treatment centers offer a dual diagnosis program. Therefore, if you struggle with mental illness, addiction or both, please call now. We want to help.
CALL NOW 1-800-951-6135